Related references
Note: Only part of the references are listed.Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
Jill Gilbert et al.
CANCER (2008)
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-κB subunits in head and neck cancer
Clint Allen et al.
CLINICAL CANCER RESEARCH (2008)
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
Carole Fakhry et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines
Jens Wagenblast et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Assessment of apoptosis-inducing effects of Docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells
Cecilia S. Jung et al.
CANCER BIOLOGY & THERAPY (2007)
Nuclear factor-κ13 in development, prevention, and therapy of cancer
Carter Van Waes
CLINICAL CANCER RESEARCH (2007)
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer
Robert Dreicer et al.
CLINICAL CANCER RESEARCH (2007)
Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma
Christine H. Chung et al.
CANCER RESEARCH (2006)
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma
RJC Slebos et al.
CLINICAL CANCER RESEARCH (2006)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis
PL Zhang et al.
MODERN PATHOLOGY (2005)
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the eastern cooperative oncology group
MK Gibson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma
A Loercher et al.
CANCER RESEARCH (2004)
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
AA Forastiere et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Significance analysis of microarrays applied to the ionizing radiation response
VG Tusher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
